Wednesday, April 25, 2012
Alexion Pharmaceuticals Inc., of Cheshire, Conn., reported net product sales of Soliris (eculizumab) of $244.7 million for the first quarter, an increase of 47 percent for the same period in 2011.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.